(Q34481227)

2 August 2017

1 reference

title

Effects of newer antipsychotics on extrapyramidal function (English)

1 reference

2 August 2017

2

Ross J Baldessarini

1 reference

2 August 2017

Daniel Tarsy

1

1 reference

PubMed ID

11772117

2 August 2017

Frank I Tarazi

series ordinal

3

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

16

1 reference

2 August 2017

23-45

1 reference

2 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200216010-00003

2 August 2017

0 references

cites work

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Tardive dyskinesia associated with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200216010-00003

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

12 December 2020

Clozapine for the control of hemiballismus.

1 reference

12 December 2020

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

1 reference

12 December 2020

Olanzapine use in the elderly: a retrospective analysis

1 reference

12 December 2020

Managing antipsychotic-induced acute and chronic akathisia

1 reference

12 December 2020

Clozapine in the treatment of tremor.

1 reference

12 December 2020

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

1 reference

12 December 2020

Risperidone-induced neuroleptic malignant syndrome in young patient

1 reference

12 December 2020

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine

1 reference

12 December 2020

Risperidone as a treatment for Tourette's syndrome.

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs.

1 reference

12 December 2020

Ten-year outcome of tardive dyskinesia

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Tolerability of atypical antipsychotics

1 reference

12 December 2020

Risperidone in treatment-refractory schizophrenia

1 reference

12 December 2020

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

12 December 2020

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias

1 reference

12 December 2020

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

12 December 2020

Risperidone-induced tardive dystonia and psychosis

1 reference

12 December 2020

Risperidone treatment of behavioral disturbances in outpatients with dementia

1 reference

12 December 2020

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

12 December 2020

1 reference

12 December 2020

Risperidone-induced tardive dyskinesia in first-episode psychotic patients

1 reference

12 December 2020

Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.

1 reference

12 December 2020

Risperidone and neuroleptic malignant syndrome

1 reference

12 December 2020

Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients

1 reference

12 December 2020

Risperidone-induced neuroleptic malignant syndrome

1 reference

12 December 2020

Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity

1 reference

12 December 2020

Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

1 reference

12 December 2020

Olanzapine in the treatment of tardive dyskinesia: a report of two cases

1 reference

12 December 2020

Antipsychotic medications and the elderly: effects on cognition and implications for use.

1 reference

12 December 2020

The treatment of tardive dyskinesia--a systematic review and meta-analysis

1 reference

12 December 2020

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group

1 reference

12 December 2020

Incidence of tardive dyskinesia: five-year data from a prospective study

1 reference

12 December 2020

Risperidone treatment of drug-related psychosis in patients with parkinsonism

1 reference

12 December 2020

The new generation of antipsychotic drugs: how atypical are they?

1 reference

12 December 2020

Olanzapine-induced agranulocytosis

1 reference

12 December 2020

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

12 December 2020

Akathisia variants and tardive dyskinesia

1 reference

12 December 2020

1 reference

12 December 2020

The emerging role of clozapine in the treatment of movement disorders

1 reference

12 December 2020

Olanzapine treatment of clozapine-induced NMS.

1 reference

12 December 2020

Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

Clozapine. A novel antipsychotic agent

1 reference

12 December 2020

Neuroleptic malignant syndrome: review and analysis of 115 cases

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Experimental neurological syndromes and the new drug therapies in psychiatry

1 reference

12 December 2020

Clozapine and risperidone treatment of psychosis in Parkinson's disease

1 reference

12 December 2020

The risks and benefits of clozapine versus chlorpromazine

1 reference

12 December 2020

Agranulocytosis during treatment with chlozapine

1 reference

12 December 2020

Risperidone for the treatment of behavioral disturbances in dementia: a case series

1 reference

12 December 2020

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

1 reference

12 December 2020

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia

1 reference

12 December 2020

A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group

1 reference

12 December 2020

Efficacy of risperidone in idiopathic segmental dystonia

1 reference

12 December 2020

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

12 December 2020

Neuropsychiatric disorders in Parkinson's disease

1 reference

12 December 2020

Extrapyramidal symptoms following Clozapine therapy. Case report

1 reference

12 December 2020

Tardive dyskinesia with quetiapine.

1 reference

12 December 2020

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

1 reference

12 December 2020

Amisulpride: its role in the therapeutic management of the schizophrenia patient. Conclusions

1 reference

12 December 2020

Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.

1 reference

12 December 2020

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia

1 reference

12 December 2020

Psychiatric manifestations of olivo-ponto-cerebellar atrophy and treatment with clozapine.

1 reference

12 December 2020

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1 reference

12 December 2020

Therapeutic strategies against tardive dyskinesia. Two decades of experience

1 reference

12 December 2020

Changes in Prevalence, Severity, and Recovery in Tardive Dyskinesia With Age

1 reference

12 December 2020

Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.

1 reference

12 December 2020

The trial use of clozapine for abnormal involuntary movement disorders

1 reference

12 December 2020

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Clozapine treatment of spasmodic torticollis.

1 reference

12 December 2020

Case report: possible neuroleptic malignant syndrome associated with olanzapine

1 reference

12 December 2020

Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications

1 reference

12 December 2020

Does clozapine cause neuroleptic malignant syndrome?

1 reference

12 December 2020

Motor and mental side effects of clozapine.

1 reference

12 December 2020

Does clozapine cause tardive dyskinesia?

1 reference

12 December 2020

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

1 reference

12 December 2020

Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations

1 reference

12 December 2020

Risperidone for psychotic and behavioural symptoms in Lewy body dementia

1 reference

12 December 2020

Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

1 reference

12 December 2020

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response

1 reference

12 December 2020

Clozapine and Clonazepam in Tardive Dystonia

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

12 December 2020

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

1 reference

12 December 2020

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.

1 reference

12 December 2020

Brain dopamine receptors: a primer on their current status, basic and clinical

1 reference

12 December 2020

Physiology of basal ganglia disorders: an overview.

1 reference

12 December 2020

Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.

1 reference

12 December 2020

Low-dose olanzapine for levodopa induced dyskinesias

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.

1 reference

12 December 2020

Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea

1 reference

12 December 2020

Reversal by physostigmine of clozapine-induced delirium

1 reference

12 December 2020

Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis

1 reference

12 December 2020

Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

1 reference

12 December 2020

A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms

1 reference

12 December 2020

Successful treatment of hemichorea with olanzapine

1 reference

12 December 2020

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

1 reference

12 December 2020

Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature

1 reference

12 December 2020

Clozapine in tardive dyskinesia

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs

1 reference

12 December 2020

Tardive Meige syndrome responsive to clozapine

1 reference

12 December 2020

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

1 reference

12 December 2020

Prevalence and severity of akathisia in patients on clozapine

1 reference

12 December 2020

An example of European multicenter trials: multispectral analysis of clozapine

1 reference

12 December 2020

Receptor pharmacology of neuroleptics: relation to clinical effects

1 reference

12 December 2020

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

1 reference

12 December 2020

Risperidone in levodopa induced dyskinesiae

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

Neuroleptic malignant syndrome associated with clozapine monotherapy

1 reference

12 December 2020

Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis

1 reference

12 December 2020

Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.

1 reference

12 December 2020

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

1 reference

12 December 2020

Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.

1 reference

12 December 2020

Neuroleptic malignant syndrome: a review of the literature

1 reference

12 December 2020

Affinity of neuroleptics for D1 receptor of human brain striatum

1 reference

12 December 2020

Low-dose clozapine improves dyskinesias in Parkinson's disease

1 reference

12 December 2020

Risperidone and tardive dyskinesia: a case report

1 reference

12 December 2020

Olanzapine: an updated review of its use in the management of schizophrenia

1 reference

12 December 2020

Clozapine-related tardive dyskinesia.

1 reference

12 December 2020

Clozapine-responsive tremor in Parkinson's disease.

1 reference

12 December 2020

Acute dystonia with quetiapine

1 reference

12 December 2020

New atypical antipsychotic medications

1 reference

12 December 2020

Clozapine and jaw dyskinesia: a case report

1 reference

12 December 2020

Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

1 reference

12 December 2020

Effect of clozapine in severe tardive dyskinesia: a case report

1 reference

12 December 2020

[Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia]

1 reference

12 December 2020

Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia

1 reference

12 December 2020

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

12 December 2020

Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.

1 reference

12 December 2020

Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.

1 reference

12 December 2020

Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study

1 reference

12 December 2020

Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject

1 reference

12 December 2020

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

1 reference

12 December 2020

Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction

1 reference

12 December 2020

The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia

1 reference

12 December 2020

Do central antiadrenergic actions contribute to the atypical properties of clozapine?

1 reference

12 December 2020

1 reference

12 December 2020

The prevalence of akathisia in patients receiving stable doses of clozapine.

1 reference

12 December 2020

An assessment of iloperidone for the treatment of schizophrenia

1 reference

12 December 2020

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.

1 reference

12 December 2020

1 reference

12 December 2020

Nocturnal akathisia in Parkinson's disease: treatment with clozapine.

1 reference

12 December 2020

Reduction of tardive dystonia with olanzapine

1 reference

12 December 2020

Barriers to progress--the impact of tolerability problems

1 reference

12 December 2020

Dopamine D4 receptors: significance for molecular psychiatry at the millennium

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic

1 reference

12 December 2020

Olanzapine-induced tardive dystonia

1 reference

12 December 2020

Review of quetiapine and its clinical applications in schizophrenia

1 reference

12 December 2020

Clozapine in Huntington's disease

1 reference

12 December 2020

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

1 reference

12 December 2020

The effects of clozapine on tardive dyskinesia

1 reference

12 December 2020

Therapeutic value of thioproperazine and the importance of the associated neurological disturbances

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine, negative symptoms, and extrapyramidal side effects

1 reference

12 December 2020

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

1 reference

12 December 2020

Clozapine in tardive dyskinesia: observations from human and animal model studies

1 reference

12 December 2020

Tardive dyskinesia induced by risperidone?

1 reference

12 December 2020

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

1 reference

12 December 2020

Risperidone in Parkinson's disease

1 reference

12 December 2020

Clozapine--a new antipsychotic agent.

1 reference

12 December 2020

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis

1 reference

12 December 2020

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.

1 reference

12 December 2020

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

1 reference

12 December 2020

Neuroleptic sensitivity to risperidone in Lewy body dementia.

1 reference

12 December 2020

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

1 reference

12 December 2020

Clozapine in Huntington's chorea

1 reference

12 December 2020

The effect of clozapine on preexisting tardive dyskinesia

1 reference

12 December 2020

Clozapine use in diffuse Lewy body disease

1 reference

12 December 2020

Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.

1 reference

12 December 2020

Paradoxical response to dopamine agonists in tardive dyskinesia

1 reference

12 December 2020

Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.

1 reference

12 December 2020

Efficacy of quetiapine in Parkinson's patients with psychosis

1 reference

12 December 2020

Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease.

1 reference

12 December 2020

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone

1 reference

12 December 2020

Marked reduction of tardive dyskinesia with olanzapine

1 reference

12 December 2020

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

1 reference

12 December 2020

Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report

1 reference

12 December 2020

Treatment of parkinsonian tremor with clozapine

1 reference

12 December 2020

Risperidone-induced tardive dyskinesia and parkinsonism

1 reference

12 December 2020

Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone

1 reference

12 December 2020

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

12 December 2020

Clozapine in the treatment of tremor in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells

1 reference

12 December 2020

A structured trial of risperidone for the treatment of agitation in dementia.

1 reference

12 December 2020

Worsening of motor features of parkinsonism with olanzapine

1 reference

12 December 2020

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Neuroleptic malignant syndrome. Review of response to therapy

1 reference

12 December 2020

10.2165/00023210-200216010-00003

Identifiers

DOI

1 reference

PubMed ID

11772117

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

11772117